Elacentra 345 mg (Elacestrant INN)

Oral SERD for Advanced Breast Cancer

💊 Pharmacology:

Elacestrant is a selective estrogen receptor degrader (SERD) that works by:

• Binding to estrogen receptors (ER)
• Inducing receptor degradation
• Blocking estrogen-driven signaling pathways
• Inhibiting tumor cell growth in ER-positive breast cancer

It is effective even in cases resistant to traditional endocrine therapies due to ESR1 mutations.

📌 Indications:

Elacentra® 345 mg is indicated for:

• Estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer
• Patients with ESR1 mutation-positive tumors
• Disease progression following prior endocrine therapy

💉 Dosage & Administration:

• Recommended dose: 345 mg once daily
• Taken orally with food
• Swallow tablets whole; do not crush or chew
• Continue treatment until disease progression or unacceptable toxicity

⚠️ Treatment should be initiated and supervised by an oncologist.

⚠️ Precautions & Warnings:

• Monitor lipid profile (cholesterol and triglycerides)
• Watch for gastrointestinal symptoms (nausea, vomiting)
• Use caution in patients with hepatic impairment
• Assess drug interactions before starting therapy

❌ Contraindications:

• Hypersensitivity to Elacestrant or any formulation component

🤰 Pregnancy & Lactation:

• Not recommended during pregnancy (risk of fetal harm)
• Breastfeeding should be avoided during treatment
• Effective contraception required during therapy

⚕️ Side Effects:

Common side effects include:

• Nausea
• Fatigue
• Vomiting
• Decreased appetite
• Arthralgia (joint pain)
• Hot flashes

Less common but serious:

• Elevated cholesterol levels
• Liver enzyme abnormalities

🧊 Storage Conditions:

• Store below 30°C
• Keep in a cool, dry place
• Protect from light and moisture
• Keep out of reach of children